Juventas Therapeutics | MedCity News

Topic: Juventas Therapeutics

Regenerative medicine company begins enrollment in critical limb ischemia trial

May 15, 2012 10:21 am by Brandon Glenn | 0 Comments

Regenerative medicine startup Juventas Therapeutics has begun enrollment in a phase 2a trial of critical limb ischemia patients.The Cleveland-based company, which recently secured an important investment from Takeda Pharmaceuticals, is ... Read more

Takeda to invest in regenerative medicine startup Juventas’ next round

May 11, 2012 2:57 pm by Brandon Glenn | 0 Comments

Takeda Pharmaceuticals is a strategic investor in regenerative medicine company Juventas Therapeutics’ upcoming series B round of funding.Juventas’ CEO Rahul Aras discussed the investment during a panel at a meeting ... Read more

Regenerative medicine startup to begin enrollment in phase 2 heart failure trial

March 15, 2012 9:28 am by Brandon Glenn | 0 Comments

Regenerative medicine startup Juventas Therapeutics is planning to begin enrollment in a phase 2 heart failure clinical trial next quarter.The Cleveland-based company’s technology, JVS-100, works by recruiting stem cells from ... Read more

Regenerative medicine company encouraged by heart failure trial

January 27, 2012 10:36 am by Brandon Glenn | 0 Comments

Regenerative medicine company Juventas Therapeutics is touting the results from 12-month data of a phase 1 clinical trial of heart failure patients.At 12 months, heart failure patients treated with the ... Read more

Juventas’ stem cell therapy shows promise in phase 1 study

May 24, 2011 1:42 pm by Brandon Glenn | 0 Comments

A phase 1 clinical trial has shown that Juventas Therapeutics‘ regenerative medicine therapy provides clinical benefit to heart failure patients.Phase 1 trials generally focus on safety, so the indication of ... Read more

Regenerative medicine startup Juventas completes phase 1 heart failure trial

April 26, 2011 12:57 pm by Brandon Glenn | 0 Comments

Cleveland Clinic spinoff Juventas Therapeutics has successfully completed a phase 1 clinical trial of its regenerative medicine technology in heart failure patients.Cleveland-based Juventas’ technology, JVS-100, works by recruiting stem cells ... Read more

Cleveland Clinic, JumpStart invest $500k in wound therapy startup

February 7, 2011 3:07 pm by Brandon Glenn | 2 Comments

SironRX hopes to raise $2.5 million, which it would use to fund a Phase 2 clinical trial of its wound-healing technology. ... Read more

Juventas Therapeutics to begin Phase 2 trial for critical limb ischemia

January 3, 2011 12:40 pm by Brandon Glenn | 0 Comments

Regenerative medicine company Juventas Therapeutics Inc. has received regulatory approval to begin a Phase 2 clinical trial of critical limb ischemia patients. ... Read more

Cleveland Clinic Innovations starts next decade with 33 companies

July 7, 2010 4:03 pm by Mary Vanac | 0 Comments

Updated 4:36 p.m.Cleveland Clinic Innovations — the corporate venturing arm of the nation’s top heart hospital — is entering its second decade with a first-of-its-kind venture ranking, a brand-new incubator ... Read more

Juventas Therapeutics starts Phase 1 trial for heart failure

April 5, 2010 3:05 pm by Mary Vanac | 0 Comments

Clinical-stage regenerative medicine company Juventas Therapeutics Inc.–a Cleveland Clinic spin-off initially named AccelleRX–has started enrolling patients in a Phase 1 clinical trial to evaluate the safety and efficacy of its ... Read more